Issue: Vol. 42

Universalised healthcare may soon be outdated as advancements in genomics, bioinformatics, and related fields are changing the face of medicine. Moving from a one-size-fits-all approach to personalised care offers major benefits, like better treatment effectiveness and cost savings by tailoring interventions to individual genetic profiles. Although there are challenges, such as needing specialised infrastructure, funding, and navigating regulations, personalised medicine has the potential to improve preventive care, optimise treatments, and create a more efficient healthcare system.

Targeted medicines continue to make headway in the battle against chronic disease, changing the prognosis for many cancer patients, with the promise of breakthroughs in other fields. But the path to development and regulatory approval for these transformational products is complex, requiring a high degree of collaboration from the outset. This is particularly critical considering the urgent need of patients awaiting innovative treatments.
There are clear benefits in therapeutic and diagnostic teams working closely together during the development of targeted therapies. Similarly, sponsors that make the most of opportunities to engage with regulators as early as possible are better positioned to navigate the path to approval.